Vimarsana
Biggest News Aggregation in the World

Page 9 - Drug Application News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Drug Application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Drug Application Today - Breaking & Trending Today

ARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Views - ARS Pharmaceuticals (NASDAQ:SPRY) - Vimarsana News

ARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Views - ARS Pharmaceuticals (NASDAQ:SPRY)

On Tuesday, The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for 

Why ARS Pharmaceuticals (SPRY) Shares Are Plunging Today - ARS Pharmaceuticals (NASDAQ:SPRY) - Vimarsana News

Why ARS Pharmaceuticals (SPRY) Shares Are Plunging Today - ARS Pharmaceuticals (NASDAQ:SPRY)

The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type I), including anaphylaxis (fatal allergic reaction) for 

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀ - Vimarsana News

PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀

19.09.2023 - Company has Successfully Completed the Production of Three Process Validation Batches at Commercial Scale Completes a Substantial Requirement Toward the Planned Submission of D-PLEX100 NDA and MAA Regulatory Filings PETACH TIKVA, Israel, Sept. ... Seite 1

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application - Vimarsana News

Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application

Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration and continue to support the requested product shelf lifeSubmission of...

Acura Pharmaceuticals : Termination of Material Agreement - Vimarsana News

Acura Pharmaceuticals : Termination of Material Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. C. 20549 FORM 8-K CURRENT REPORT Pursuant to... -Today at 11:24 am- MarketScreener